DURECT Corporation (Nasdaq: DRRX) 48% LOWER; announced top-line results from the U.S. pivotal Phase III clinical study for POSIDUR® known as BESST which did not meet statistical significance. Click here to see the full report.
RF Micro Devices, Inc. (Nasdaq: RFMD) 15.9% LOWER; has provided a quarterly financial update for its third fiscal quarter, ended December 31, 2011.